Clinical Trial

MR Spectroscopy and Imaging in Brain Cancers

Study Description

Clinical Development of MR Spectroscopy and Imaging in Brain Cancers

The Investigators will examine the disease specificity of 2-hydroxyglutarate in non-glioma brain lesions, and the clinical utility of 2-hydroxyglutarate, glycine and citrate in isocitrate dehydrogenase (IDH) mutated gliomas and IDH wild type gliomas.

Location

Locations Selected Location

Methods

No pharmaceutical medication involved No pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Device - 3 Tesla Scanning

Approximately 120 brain tumor patients 50 patients with non-glioma disease, and 5 healthy volunteers will be scanned at either 3 Tesla or 7 Tesla.

Device - 7 Tesla Scanning

Approximately 120 brain tumor patients 50 patients with non-glioma disease, and 5 healthy volunteers will be scanned at either 3 Tesla or 7 Tesla.

Additional Information

Official Study Title

Clinical Development of MR Spectroscopy and Imaging in Brain Cancers

Clinical Trial ID

NCT02731521

ParticipAid ID

nel61b